The active ingredient of Degra tablets is Degra citrate. Degra prevents the action of phosphodiesterase type 5 which breaks down cyclic GMP in the blood vessel walls. Cyclic GMP relaxes blood muscles and increases blood flow to penis. Penis becomes erect and rigid. Inhibiting the action of phosphodiesterase type 5 causes stopping the breakdown of cyclic GMP. Blood vessels can be dilated for longer, increasing blood flow to the penis and maintaining an erection. Indications: erectile dysfunction(Impotence) in men. Degra is used to treat erectile dysfunction (impotence) in men. Degra will aid in an erection only if you are sexually stimulated. Oral Erectile dysfunction Adult: 50 mg about 1 hr before sexual intercourse. May adjust dose depending on penile response. Max: 100 mg/dose and not to be taken > once in 24 hr. Elderly: >65 yr: Lower initial dose at 25 mg. CrCl (ml/min) Dosage Recommendation <30 Initially, 25 mg. Hepatic impairment: Initially, 25 mg. Special Populations: For patients taking drugs which are CYP3A4 inhibitors: initially, 25 mg. For patients on ritanavir, not >25 mg every 48 hr. Patients who are stabilised on α-blocker treatment should use an initial dose of 25 mg. Higher doses should not be taken within 4 hr of an α-blocker. Degra is used to treat a lung disease known as pulmonary arterial hypertension (PAH). PAH causes breathlessness and tiredness during exercise and at rest. Degra helps to improve exercise ability in people who have PAH. Oral Erectile dysfunction Adult: 50 mg about 1 hr before sexual intercourse. May adjust dose depending on penile response. Max: 100 mg/dose and not to be taken > once in 24 hr. Elderly: >65 yr: Lower initial dose at 25 mg. CrCl (ml/min) Dosage Recommendation <30 Initially, 25 mg. Hepatic impairment: Initially, 25 mg. Special Populations: Patients with hepatic or renal impairment (creatinine clearance <30 mL/min): 25 mg. Degra Teva is a medication for the treatment of erectile dysfunction. This drug restores impaired erectile function and provides a natural response to sexual stimulation. Degra is a potent and selective inhibitor of cGMP-specific phosphodiesterase type 5 (PDE5) which is responsible for the breakdown of cGMP in the cavernous body. This medicine has no direct relaxing effect on corpus cavernosum, but enhances the relaxing effect of active nitric oxide in this tissue. When sexually aroused the local release of NO under the influence of Degra leads to the inhibition of PDE-5 and increase of cGMP in the cavernous body, resulting in relaxation of smooth muscles and increasing blood flow to the cavernous body. Degra may cause mild and transient violation of distinguishing colors (blue / green). Alleged violations of the mechanism of color vision is PDE6 oppression, which is involved in the transmission of light in the retina.
